Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.

por Tartour, E., Dorval, T., Mosseri, V., Deneux, L., Mathiot, C., Brailly, H., Montero, F., Joyeux, I., Pouillart, P., Fridman, W. H.
Publicado 1994

Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings

por Tartour, E, Mehtali, M, Sastre-Garau, X, Joyeux, I, Mathiot, C, Pleau, J M, Squiban, P, Rochlitz, C, Courtney, M, Jantscheff, P, Herrmann, R, Pouillart, P, Fridman, W H, Dorval, T
Publicado 2000